Literature DB >> 17373970

Stigmatization experience, coping and sense of coherence in vitiligo patients.

G Schmid-Ott1, H-W Künsebeck, E Jecht, R Shimshoni, I Lazaroff, S Schallmayer, I T Calliess, P Malewski, F Lamprecht, A Götz.   

Abstract

OBJECTIVE: This study examines the extent of stigmatization experienced by vitiligo patients considering the visibility of the lesions.
METHODS: 363 vitiligo patients were assessed using the Experience with Skin Complaints (QES), Adjustment to Chronic Skin Disorders (ASC), and Sense of Coherence (SOC) questionnaires. Out of the total patients group two representative samples with 52 patients each were identified comparable for age, gender, and the duration of the skin disease, the first with visible and the second with invisible lesions.
RESULTS: Data indicate a significant negative correlation between the QES dimensions, except for 'Composure', and between coping scales with sense of coherence withstanding. The 'visible lesions' group scored higher compared to the 'invisible lesions' group on the two QES scales 'Self-Esteem' and 'Refusal', i.e., patients with visible lesions experienced a higher level of stigmatization.
CONCLUSION: This study provides new information which supports the notion that the stigmatization experience of vitiligo patients is psychologically relevant.

Entities:  

Mesh:

Year:  2007        PMID: 17373970     DOI: 10.1111/j.1468-3083.2006.01897.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  13 in total

1.  Prevalence and risk factors of depression in geriatric patients with dermatological diseases.

Authors:  Eun Kyung Kim; Hyung Ok Kim; Young Min Park; Chul Jong Park; Dong Su Yu; Jun Young Lee
Journal:  Ann Dermatol       Date:  2013-08-13       Impact factor: 1.444

Review 2.  Psychosocial aspects of rosacea with a focus on anxiety and depression.

Authors:  Monika Heisig; Adam Reich
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-03-06

3.  Gender Differences in Depression, Coping, Stigma, and Quality of Life in Patients of Vitiligo.

Authors:  Neena S Sawant; Nakul A Vanjari; Uday Khopkar
Journal:  Dermatol Res Pract       Date:  2019-04-02

4.  Objective Assessment of Skin Repigmentation Using a Multilayer Perceptron.

Authors:  Juan Fernando Chica; Sayonara Zaputt; Javier Encalada; Christian Salamea; Melissa Montalvo
Journal:  J Med Signals Sens       Date:  2019 Apr-Jun

5.  Meta-Analytic Review of High Anxiety Comorbidity among Patients with Vitiligo.

Authors:  Jiani Liu; Rui Tang; Yangfan Xiao; Mei Luo; Yaqian Shi; Qiancheng Deng; Huiming Zhang; Zhoutong Zeng; Zixin Pi; Rong Xiao
Journal:  Biomed Res Int       Date:  2021-05-17       Impact factor: 3.411

6.  Clinical patterns of vitiligo and its associated co morbidities: A prospective controlled cross-sectional study in South India.

Authors:  D S Krupa Shankar; K Shashikala; Rama Madala
Journal:  Indian Dermatol Online J       Date:  2012-05

Review 7.  Immunological Parameters Associated With Vitiligo Treatments: A Literature Review Based on Clinical Studies.

Authors:  Ana Cláudia Guimarães Abreu; Gabriela Guy Duarte; Juliana Yasmin Pains Miranda; Daniel Gontijo Ramos; Camila Gontijo Ramos; Mariana Gontijo Ramos
Journal:  Autoimmune Dis       Date:  2015-09-17

8.  Comparison of the psychological impacts of asymptomatic and symptomatic cutaneous diseases: vitiligo and atopic dermatitis.

Authors:  Seongmin Noh; Miri Kim; Chang Ook Park; Seung-Kyung Hann; Sang Ho Oh
Journal:  Ann Dermatol       Date:  2013-11-30       Impact factor: 1.444

9.  The Perceived Stigma in Patients with Alopecia and Mental Disorder: A Comparative Study.

Authors:  Seval Dogruk Kacar; Ethem Soyucok; Erman Bagcioglu; Pınar Ozuguz; Kerem Senol Coskun; Ahmet Hakki Asık; Hasan Mayda
Journal:  Int J Trichology       Date:  2016 Jul-Sep

10.  Correlation of clinical efficacy and psychosocial impact on vitiligo patients by excimer laser treatment.

Authors:  Hani A Al-Shobaili
Journal:  Ann Saudi Med       Date:  2014 Mar-Apr       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.